CPC C07K 16/244 (2013.01) [C07K 14/5428 (2013.01); C07K 14/7155 (2013.01); C07K 16/2866 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/32 (2013.01); C07K 2319/43 (2013.01); C12N 2310/14 (2013.01)] | 15 Claims |
1. A method of treating fibrosis in a human subject, the method comprising administering to the human subject in need of treatment, a therapeutically effective amount of a human or humanized monoclonal anti-human Interleukin 11 (IL-11) antibody which inhibits IL-11 mediated signaling;
wherein an antibody that inhibits IL-11 mediated signaling is an antibody which inhibits transforming growth factor beta 1 (TGF(31)-mediated activation of human fibroblasts to alpha smooth muscle actin (αSMA)-positive fibroblasts.
|